Safety and tolerability of once-weekly GLP-1 receptor agonists in type 2 diabetes.

Published in: Journal of clinical pharmacy and therapeutics (2021)

This review puts the latest clinical data from the marketed QW GLP-1 RAs into context with results from older Phase 3 trials, to enable pharmacists and HCPs to make informed treatment decisions. Each of the three QW GLP-1 RAs has their own safety profile, which should be considered when choosing the optimal treatment for patients.

Keyphrases

type diabetes
ejection fraction
newly diagnosed
physical activity
clinical trial
open label
electronic health record
randomized controlled trial
artificial intelligence
smoking cessation